Empyrean is developing genetic engineering therapies that enhance neuroactive compounds derived from plants and fungi to treat severe neuropsychiatric and neurological disorders, including depression and PTSD. The company targets the significant unmet need for effective treatments in a healthcare landscape where current options are limited and often inadequate.
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for severe neuropsychiatric and neurological disorders, such as depression and PTSD, often prove inadequate, leaving a significant unmet need for more effective therapeutic options. Existing pharmaceutical interventions may have limited efficacy or undesirable side effects, highlighting the necessity for innovative approaches.
Solution
Empyrean is developing novel genetic engineering therapies designed to enhance the efficacy of neuroactive compounds derived from plants and fungi. By potentiating these naturally occurring compounds, Empyrean aims to create more effective treatments for severe neuropsychiatric and neurological disorders, including depression, post-traumatic stress disorder, substance abuse disorders, and pain. Their approach focuses on addressing the limitations of current treatments by leveraging the therapeutic potential of genetically modified neuroactive substances.
Target Audience
The primary target audience includes individuals suffering from severe neuropsychiatric and neurological disorders, such as depression and PTSD, who are seeking more effective treatment options.
Features
- Genetic engineering of plants and fungi to produce enhanced neuroactive compounds.
- Targeted therapies for depression, PTSD, substance abuse disorders, and pain.
- Focus on potentiating naturally derived compounds for improved efficacy.